{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:47:54Z","timestamp":1793922474897,"version":"4.8.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T00:00:00Z","timestamp":1570752000000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2014R1A5A20009936"],"award-info":[{"award-number":["2014R1A5A20009936"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1C1B2005982"],"award-info":[{"award-number":["2017R1C1B2005982"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p>Angiogenesis should be precisely regulated because disordered neovascularization is involved in the aggravation of multiple diseases. The vascular endothelial growth factor (VEGF)-A\/VEGF receptor 2 (VEGFR-2) axis is crucial for controlling angiogenic responses in vascular endothelial cells (ECs). Therefore, inactivating VEGFR-2 signaling may effectively suppress aberrant angiogenesis and alleviate related symptoms. In this study, we performed virtual screening, identified the synthetic disaccharide 6\u2032-sialylgalactose (6SG) as a potent VEGFR-2-binding compound and verified its high binding affinity by Biacore assay. 6SG effectively suppressed VEGF-A-induced VEGFR-2 phosphorylation and subsequent in vitro angiogenesis in HUVECs without inducing cytotoxicity. 6SG also inhibited VEGF-A-induced extracellular-regulated kinase (ERK)\/Akt activation and actin stress fiber formation in HUVECs. We demonstrated that 6SG inhibited retinal angiogenesis in a mouse model of retinopathy of prematurity and tumor angiogenesis in a xenograft mouse model. Our results suggest a potential therapeutic benefit of 6SG in inhibiting angiogenesis in proangiogenic diseases, such as retinopathy and cancer.<\/jats:p>","DOI":"10.1038\/s12276-019-0311-6","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T06:59:30Z","timestamp":1570777170000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["6\u2032-Sialylgalactose inhibits vascular endothelial growth factor receptor 2-mediated angiogenesis"],"prefix":"10.1038","volume":"51","author":[{"given":"Tae-Wook","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Yeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Jung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Woo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Bok","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keuk-Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Jun","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6283-0171","authenticated-orcid":false,"given":"Ki-Tae","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,11]]},"reference":[{"key":"311_CR1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0008-6363(00)00281-9","volume":"49","author":"EM Conway","year":"2001","unstructured":"Conway, E. M., Collen, D. & Carmeliet, P. Molecular mechanisms of blood vessel growth. Cardiovasc. Res. 49, 507\u2013521 (2001).","journal-title":"Cardiovasc. Res."},{"key":"311_CR2","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature04483","volume":"438","author":"N Ferrara","year":"2005","unstructured":"Ferrara, N. & Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 438, 967\u2013974 (2005).","journal-title":"Nature"},{"key":"311_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10456-015-9477-2","volume":"18","author":"HA Elshabrawy","year":"2015","unstructured":"Elshabrawy, H. A. et al. The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis 18, 433\u2013448 (2015).","journal-title":"Angiogenesis"},{"key":"311_CR4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.yexcr.2005.11.012","volume":"312","author":"M Shibuya","year":"2006","unstructured":"Shibuya, M. & Claesson-Welsh, L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res. 312, 549\u2013560 (2006).","journal-title":"Exp. Cell Res."},{"key":"311_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4062\/biomolther.2013.113","volume":"22","author":"M Shibuya","year":"2014","unstructured":"Shibuya, M. VEGF-VEGFR signals in health and disease. Biomol. Ther. 22, 1\u20139 (2014).","journal-title":"Biomol. Ther."},{"key":"311_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.molmed.2011.01.015","volume":"17","author":"P Saharinen","year":"2011","unstructured":"Saharinen, P., Eklund, L., Pulkki, K., Bono, P. & Alitalo, K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol. Med. 17, 347\u2013362 (2011).","journal-title":"Trends Mol. Med."},{"key":"311_CR7","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335\u20132342 (2004).","journal-title":"N. Engl. J. Med."},{"key":"311_CR8","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","volume":"28","author":"JL Spratlin","year":"2010","unstructured":"Spratlin, J. L. et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G(1) monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol. 28, 780\u2013787 (2010).","journal-title":"J. Clin. Oncol."},{"key":"311_CR9","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584\u20133590 (2009).","journal-title":"J. Clin. Oncol."},{"key":"311_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ccr.2010.07.001","volume":"18","author":"YJ Koh","year":"2010","unstructured":"Koh, Y. J. et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 18, 171\u2013184 (2010).","journal-title":"Cancer Cell"},{"key":"311_CR11","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.urology.2010.04.025","volume":"76","author":"P Twardowski","year":"2010","unstructured":"Twardowski, P. et al. Phase II study of aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a california cancer consortium trial. Urology 76, 923\u2013926 (2010).","journal-title":"Urology"},{"key":"311_CR12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1055\/s-0043-102949","volume":"83","author":"AR Bilia","year":"2017","unstructured":"Bilia, A. R. et al. Improving on nature: the role of nanomedicine in the development of clinical natural drugs. Planta Med. 83, 366\u2013381 (2017).","journal-title":"Planta Med."},{"key":"311_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2174\/138920307781369427","volume":"8","author":"AS Reddy","year":"2007","unstructured":"Reddy, A. S., Pati, S. P., Kumar, P. P., Pradeep, H. N. & Sastry, G. N. Virtual screening in drug discovery\u2014a computational perspective. Curr. Protein Pept. Sci. 8, 329\u2013351 (2007).","journal-title":"Curr. Protein Pept. Sci."},{"key":"311_CR14","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nature03197","volume":"432","author":"BK Shoichet","year":"2004","unstructured":"Shoichet, B. K. Virtual screening of chemical libraries. Nature 432, 862\u2013865 (2004).","journal-title":"Nature"},{"key":"311_CR15","first-page":"771","volume":"41","author":"DH Lee","year":"2018","unstructured":"Lee, D. H. et al. Oleanolic acids inhibit vascular endothelial growth factor receptor 2 signaling in endothelial cells: implication for anti-angiogenic therapy. Molecules Cells 41, 771\u2013780 (2018).","journal-title":"Molecules Cells"},{"key":"311_CR16","doi-asserted-by":"publisher","first-page":"58152","DOI":"10.18632\/oncotarget.16192","volume":"8","author":"TW Chung","year":"2017","unstructured":"Chung, T. W. et al. Sialyllactose suppresses angiogenesis by inhibiting VEGFR-2 activation, and tumor progression. Oncotarget 8, 58152\u201358162, \nhttps:\/\/doi.org\/10.18632\/oncotarget.16192\n\n (2017).","journal-title":"Oncotarget"},{"key":"311_CR17","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1093\/jn\/134.11.3016","volume":"134","author":"L Bode","year":"2004","unstructured":"Bode, L., Beermann, C., Mank, M., Kohn, G. & Boehm, G. Human and bovine milk ganliosides in their fatty acid composition. J. Nutr. 134, 3016\u20133020 (2004).","journal-title":"J. Nutr."},{"key":"311_CR18","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1021\/pr101006u","volume":"10","author":"SA Wu","year":"2011","unstructured":"Wu, S. A., Grimm, R., German, J. B. & Lebrilla, C. B. Annotation and structural analysis of sialylated human milk oligosaccharides. J. Proteome Res. 10, 856\u2013868 (2011).","journal-title":"J. Proteome Res."},{"key":"311_CR19","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/glycob\/cws074","volume":"22","author":"L Bode","year":"2012","unstructured":"Bode, L. Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology 22, 1147\u20131162, \nhttps:\/\/doi.org\/10.1093\/glycob\/cws074\n\n (2012).","journal-title":"Glycobiology"},{"key":"311_CR20","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1021\/ol801519j","volume":"10","author":"T Watanabe","year":"2008","unstructured":"Watanabe, T. et al. Synthesis of CH2-linked alpha(2,3)sialylgalactose analogue: on the stereoselectivity of the key Ireland-Claisen rearrangement. Org. Lett. 10, 4167\u20134170, \nhttps:\/\/doi.org\/10.1021\/ol801519j\n\n (2008).","journal-title":"Org. Lett."},{"key":"311_CR21","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1021\/jm801570y","volume":"52","author":"T Matsubara","year":"2009","unstructured":"Matsubara, T. et al. Inhibition of influenza virus infections by sialylgalactose-binding peptides selected from a phage library. J. Med Chem. 52, 4247\u20134256, \nhttps:\/\/doi.org\/10.1021\/jm801570y\n\n (2009).","journal-title":"J. Med Chem."},{"key":"311_CR22","doi-asserted-by":"publisher","first-page":"11197","DOI":"10.1074\/jbc.273.18.11197","volume":"273","author":"G Fuh","year":"1998","unstructured":"Fuh, G., Li, B., Crowley, C., Cunningham, B. & Wells, J. A. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J. Biol. Chem. 273, 11197\u201311204 (1998).","journal-title":"J. Biol. Chem."},{"key":"311_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00109-012-0952-6","volume":"91","author":"TW Chung","year":"2013","unstructured":"Chung, T. W. et al. CAPE suppresses VEGFR-2 activation, and tumor neovascularization and growth. J. Mol. Med (Berl.) 91, 271\u2013282, \nhttps:\/\/doi.org\/10.1007\/s00109-012-0952-6\n\n (2013).","journal-title":"J. Mol. Med (Berl.)"},{"issue":"3","key":"311_CR24","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.cell.2014.09.025","volume":"159","author":"Keisuke Okabe","year":"2014","unstructured":"Okabe, K. et al. Neurons limit angiogenesis by titrating VEGF in retina. Cell 159, 584\u2013596, \nhttps:\/\/doi.org\/10.1016\/j.cell.2014.09.025\n\n (2014).","journal-title":"Cell"},{"key":"311_CR25","first-page":"101","volume":"35","author":"LE Smith","year":"1994","unstructured":"Smith, L. E. et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol. Vis. Sci. 35, 101\u2013111 (1994).","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"311_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6758","volume":"5","author":"C Xu","year":"2014","unstructured":"Xu, C. et al. Arteries are formed by vein-derived endothelial tip cells. Nat. Commun. 5, 5758, \nhttps:\/\/doi.org\/10.1038\/ncomms6758\n\n (2014).","journal-title":"Nat. Commun."},{"issue":"11","key":"311_CR27","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/nprot.2009.187","volume":"4","author":"Kip M Connor","year":"2009","unstructured":"Connor, K. M. et al. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc. 4, 1565\u20131573, \nhttps:\/\/doi.org\/10.1038\/nprot.2009.187\n\n (2009).","journal-title":"Nature Protocols"},{"key":"311_CR28","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1208\/s12248-012-9353-6","volume":"14","author":"T Prueksaritanont","year":"2012","unstructured":"Prueksaritanont, T. & Tang, C. Y. ADME of biologics\u2014what have we learned from small molecules? Aaps J. 14, 410\u2013419 (2012).","journal-title":"Aaps J."},{"key":"311_CR29","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jgr.2016.10.005","volume":"41","author":"K Park","year":"2017","unstructured":"Park, K. & Cho, A. E. Using reverse docking to identify potential targets for ginsenosides. J. Ginseng Res. 41, 534\u2013539 (2017).","journal-title":"J. Ginseng Res."},{"key":"311_CR30","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nrd1549","volume":"3","author":"DB Kitchen","year":"2004","unstructured":"Kitchen, D. B., Decornez, H., Furr, J. R. & Bajorath, J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug Discov. 3, 935\u2013949 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"311_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/sj.onc.1209002","volume":"25","author":"PFT Cezar-de-Mello","year":"2006","unstructured":"Cezar-de-Mello, P. F. T., Nascimento-Silva, V., Villela, C. G., Fierro, I. M. Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly. Oncogene 25, 122\u2013129 \nhttps:\/\/doi.org\/10.1038\/sj.onc.1209002\n\n (2006).","journal-title":"Oncogene"},{"key":"311_CR32","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","volume":"382","author":"A Hellstrom","year":"2013","unstructured":"Hellstrom, A., Smith, L. E. H. & Dammann, O. Retinopathy of prematurity. Lancet 382, 1445\u20131457 (2013).","journal-title":"Lancet"},{"key":"311_CR33","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1172\/JCI42142","volume":"120","author":"P Sapieha","year":"2010","unstructured":"Sapieha, P. et al. Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. J. Clin. Investig. 120, 3022\u20133032 (2010).","journal-title":"J. Clin. Investig."},{"key":"311_CR34","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ajo.2009.05.031","volume":"148","author":"JA Micieli","year":"2009","unstructured":"Micieli, J. A., Surkont, M. & Smith, A. F. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am. J. Ophthalmol. 148, 536\u2013543 (2009).","journal-title":"Am. J. Ophthalmol."},{"key":"311_CR35","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/j.1442-200X.2007.02483.x","volume":"49","author":"T Okamoto","year":"2007","unstructured":"Okamoto, T. et al. Human milk reduces the risk of retinal detachment in extremely low-birthweight infants. Pediatrics Int. 49, 894\u2013897 (2007).","journal-title":"Pediatrics Int."},{"key":"311_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1055\/s-0031-1295652","volume":"29","author":"A Maayan-Metzger","year":"2012","unstructured":"Maayan-Metzger, A., Avivi, S., Schushan-Eisen, I. & Kuint, J. Human milk versus formula feeding among preterm infants: short-term outcomes. Am. J. Perinatol. 29, 121\u2013126 (2012).","journal-title":"Am. J. Perinatol."},{"key":"311_CR37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cell.2008.01.021","volume":"132","author":"RSJudahFolkman Kerbel","year":"2008","unstructured":"Kerbel, R. S. JudahFolkman 1933-2008\u2014obituary. Cell 132, 333\u2013334 (2008).","journal-title":"Cell"},{"key":"311_CR38","first-page":"1537","volume":"34","author":"S Lauro","year":"2014","unstructured":"Lauro, S., Onesti, C. E., Righini, R. & Marchetti, P. The use of bevacizumab in non-small cell lung cancer: an update. Anticancer Res. 34, 1537\u20131545 (2014).","journal-title":"Anticancer Res."},{"key":"311_CR39","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1634\/theoncologist.2012-0003","volume":"17","author":"JH Strickler","year":"2012","unstructured":"Strickler, J. H. & Hurwitz, H. I. Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist 17, 513\u2013524 (2012).","journal-title":"Oncologist"},{"key":"311_CR40","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1172\/JCI93182","volume":"127","author":"K Jung","year":"2017","unstructured":"Jung, K. et al. Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. J. Clin. Invest 127, 3039\u20133051, \nhttps:\/\/doi.org\/10.1172\/JCI93182\n\n (2017).","journal-title":"J. Clin. Invest"},{"key":"311_CR41","doi-asserted-by":"publisher","first-page":"10455","DOI":"10.1073\/pnas.1710754114","volume":"114","author":"K Jung","year":"2017","unstructured":"Jung, K. et al. Targeting CXCR4-dependent immunosuppressive Ly6C(low) monocytes improves antiangiogenic therapy in colorectal cancer. Proc. Natl Acad. Sci. USA 114, 10455\u201310460, \nhttps:\/\/doi.org\/10.1073\/pnas.1710754114\n\n (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"4","key":"311_CR42","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.celrep.2015.03.055","volume":"11","author":"Lee\u00a0B. Rivera","year":"2015","unstructured":"Rivera, L. B. et al. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell Rep 11, 577\u2013591, \nhttps:\/\/doi.org\/10.1016\/j.celrep.2015.03.055\n\n (2015).","journal-title":"Cell Reports"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s12276-019-0311-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s12276-019-0311-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s12276-019-0311-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:10:58Z","timestamp":1684617058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-019-0311-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["311"],"URL":"https:\/\/doi.org\/10.1038\/s12276-019-0311-6","relation":{},"ISSN":["1226-3613","2092-6413"],"issn-type":[{"value":"1226-3613","type":"print"},{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"3 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}